-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 28th, the CDE official website revealed that Lepu Biologic’s Pucotenlimab injection (pucotenlimab, HX008) is planned to be included in the priority review for the treatment of highly unstable microsatellites ( Patients with advanced solid tumors with MSI-H) or defective mismatch repair (dMMR)
Pratlizumab is a humanized anti-PD-1 monoclonal antibody that can antagonize PD-1 signal and restore immune cell killing by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2 The ability of cancer cells
On October 26, the listing application of Lepu Bio's PD-1 monoclonal antibody Pratlizumab for the treatment of MSI-H/dMMR solid tumors was accepted by the NMPA
Previously, Pratlizumab conducted a phase II clinical trial for the treatment of highly microsatellite unstable (MSI-H) or defective mismatch repair (dMMR) advanced solid tumors as a single agent.
According to inexhaustible statistics, among the common cancer types, the number of new MSI-H solid tumor patients in China each year is about 310,000.
